Here we report an activity-dependent stabilization of the MAP kinase (MAPK) pathway, prominent in hippocampal dendrites. The longevity of the signal in these dendrites was increased to hours when ...

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will ...

Copyright held by the owner/author(s).

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

Department of Neurosurgery, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Road, Nanchang, Jiangxi 330006, China Department of ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

【导读】子宫内膜癌（EC）是威胁妇女健康的重大疾病，治疗后的复发是一大挑战。虽然胆固醇代谢异常被认为与子宫内膜癌的进展有关，但其潜在机制仍不清楚。在这项研究中，团队发现羊毛甾醇合成酶（LSS）是与乳腺癌相关的胆固醇代谢的关键介质。2025年2月8日， ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.